On Feb. 7, AstraZeneca announced it received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

AstraZeneca (AZN) halts Truqap trial for prostate cancer after an independent review finds it unlikely to meet survival or ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...